The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex
文献类型：期刊论文
| 作者 | Wang, Shixiang2,3,4; Zhang, Jing2,3,4; He, Zaoke2,3,4; Liu, Xue-Song4; Wu, Kai1; , |
| 刊名 | INTERNATIONAL JOURNAL OF CANCER
 |
| 出版日期 | 2019 |
| 卷号 | 145期号:10页码:2840-2849 |
| 关键词 | PD-1 BLOCKADE CLINICAL-RESPONSE SOLID TUMORS NIVOLUMAB IPILIMUMAB PEMBROLIZUMAB CHEMOTHERAPY RESISTANCE LANDSCAPE DOCETAXEL |
| ISSN号 | 0020-7136 |
| DOI | 10.1002/ijc.32327 |
| 文献子类 | Article |
| 英文摘要 | Immunotherapy, represented by immune checkpoint inhibitors (ICI), is transforming the treatment of cancer. However, only a fraction of patients show response to ICI, and there is an unmet need for biomarkers that will identify patients more likely to respond to ICI. Here we report that the ICI response prediction biomarker tumor mutational burden (TMB) shows significant sex differences. TMB's predictive power is significantly better for female than for male lung cancer patients. Receiver operating characteristic curve analysis was performed and the area under the curve (AUC) was reported to evaluate the predictive power of TMB in lung cancer ICI response. Hazard ratios (HR) of TMB-high vs. TMB-low patients were compared between male and female patients. Both AUC and HR differences between female and male are significant in all available independent lung cancer datasets. However, the AUC of programmed death ligand 1 (PD-L1) expression does not show a difference between female and male, suggesting TMB, but not PD-L1 expression has a better predictive power for female than for male lung cancer patients. Our study suggests significant sex differences in the performance of TMB in ICI response prediction. Future development of ICI biomarker should consider sex differences and special efforts should be paid to improve the performance of ICI predictive biomarkers for male lung cancer patients. |
| 学科主题 | Oncology |
| WOS关键词 | tumor mutational burden ; cancer immunotherapy ; immune checkpoint inhibitors ; lung cancer ; sex differences |
| 语种 | 英语 |
| WOS记录号 | WOS:000486192300023 |
| 版本 | 出版稿 |
| 源URL | [http://202.127.25.143/handle/331003/3530]  |
| 专题 | 生化所2019-2020年发文 |
| 作者单位 | 1.Zhengzhou Univ, Affiliated Hosp 1, Dept Thorac Surg, Zhengzhou, Henan, Peoples R China, 2.Univ Chinese Acad Sci, Beijing, Peoples R China; 3.Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Shanghai, Peoples R China; 4.ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201203, Peoples R China; |
| 推荐引用方式 GB/T 7714 | Wang, Shixiang,Zhang, Jing,He, Zaoke,et al. The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex[J]. INTERNATIONAL JOURNAL OF CANCER,2019,145(10):2840-2849. |
| APA | Wang, Shixiang,Zhang, Jing,He, Zaoke,Liu, Xue-Song,Wu, Kai,&,.(2019).The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex.INTERNATIONAL JOURNAL OF CANCER,145(10),2840-2849. |
| MLA | Wang, Shixiang,et al."The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex".INTERNATIONAL JOURNAL OF CANCER 145.10(2019):2840-2849. |
入库方式： OAI收割
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。